A new era in managing DKD: Improving outcomes with empagliflozin/linagliptin combination therapy

01 Aug 2021
DKD is the principal cause of ESRD and remains one of the most prevalent complications among patients with T2DM.Hyperglycaemia is the main factor in the development and progression of DKD; once established, it triggers multiple pathogenic processes (eg, hypertension, altered tubuloglomerular feedback, renal hypoxia, lipotoxicity, inflammation), leading to a progressive decline in GFR.

Related MIMS Drugs

Editor's Recommendations